Dermatologic treatment of cutaneous graft versus host disease.
Cutaneous involvement in graft versus host disease (GVHD) after allogeneic hematopoietic cell transplant can be separated into acute GVHD (aGVHD), lichenoid chronic GVHD (cGVHD) and sclerodermatous cGVHD. It seems clear that these syndromes result from different mechanisms and entail different treatment approaches. Standard treatment of cutaneous aGVHD involves the intensification of immunosuppressive therapy with adequate topical supportive management. In skin-limited disease, phototherapy has shown promising results. In cutaneous cGVHD, the combination of corticosteroids and cyclosporine (ciclosporin) is the recommended therapy, and other immunosuppressants may be added depending on whether lichenoid or sclerodermatous lesions are present. High response rates to phototherapy have been found in lichenoid disease, while sclerodermatous disease responds better to etretinate or extracorporeal photochemotherapy. Localized cutaneous cGVHD may be treated with topical corticosteroids alone. Few reports on the effect of treatments in GVHD clearly describe the cutaneous involvement and the influence of the treatment on the skin. Therefore, dermatologists should be deeply involved in the diagnosis and treatment of GVHD, and good dermatologic grading systems should be developed. Theses changes will increase our knowledge of cutaneous GVHD, and relevant data in the evaluation of the effect of therapy in the disease will be obtained.
Peñas
Pablo F
PF
Department of Dermatology, Hospital Universitario de la Princesa, Madrid, Spain. pablofp@aedv.es
Fernández-Herrera
Jesús
J
García-Diez
Amaro
A
D002986:Clinical Trials as Topic; D005050:Etretinate / Q000008:administration & dosage; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D011701:PUVA Therapy; D012871:Skin Diseases / Q000188:drug therapy* / Q000473:pathology; D013792:Thalidomide / Q000008:administration & dosage; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D013792:Thalidomide; D005050:Etretinate